The safety and tolerability of a one strength dose-escalation scheme for subcutaneous immunotherapy with a native house dust mite extract in Chinese children: A multicenter, randomized, open label clinical trial
- Resource Type
- Article
- Source
- In
Heliyon 30 April 2024 10(8) - Subject
- Language
- ISSN
- 2405-8440